Bush Karen, Bradford Patricia A
Molecular and Cellular Biochemistry, Indiana University, Bloomington, Indiana 47405.
AstraZeneca Pharmaceuticals, Waltham, Massachusetts 02451.
Cold Spring Harb Perspect Med. 2016 Aug 1;6(8):a025247. doi: 10.1101/cshperspect.a025247.
β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of β-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options. This work provides a comprehensive overview of β-lactam antibiotics that are currently in use, as well as a look ahead to several new compounds that are in the development pipeline.
β-内酰胺类是使用最广泛的一类抗生素。自20世纪20年代发现苄青霉素以来,已发现了数千种新的青霉素衍生物以及相关的β-内酰胺类头孢菌素、头霉素、单环β-内酰胺类和碳青霉烯类。每一类新的β-内酰胺类药物的研发,要么是为了扩大活性谱以涵盖更多细菌种类,要么是为了解决目标细菌群体中出现的特定耐药机制。对β-内酰胺类药物的耐药性主要是由于细菌产生的β-内酰胺酶,这些酶会水解β-内酰胺环,从而使药物失活。规避耐药性的最新努力是开发新型广谱β-内酰胺酶抑制剂,这些抑制剂可对抗许多有问题的β-内酰胺酶,包括头孢菌素酶和丝氨酸类碳青霉烯酶,这些酶严重限制了治疗选择。这项工作全面概述了目前正在使用的β-内酰胺类抗生素,并展望了几种正在研发中的新化合物。